Comparison of High Ribavirin Induction versus Standard Ribavirin Dosing, plus Peginterferon-α for the Treatment of Chronic Hepatitis C in HIV-Infected Patients: The PERICO Trial
The Journal of Infectious Diseases,
Labarga P et al. – A 4–week induction therapy with high RBV dosing along with erythropoietin does not improve SVR rates in HIV/HCV–coinfected patients. Pre–emptive erythropoietin might blunt the benefit of RBV overdosing by enhancing erythrocyte uptake of plasma RBV.